Physician profile
Ryan Nguyen
NPI 1831288406
$2,534.04
in general payments reported to CMS, 2019-2025
19 companies · $2,206 in 2025
The $2,206 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $61.76 · 2024: $267 · 2025: $2,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $447.24 | 2025 | Erzofri Extended-Release |
| Vanda Pharmaceuticals INC. | $422.58 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $376.24 | 2025 | Invega Trinza, Invega Sustenna |
| Amgen INC. | $259.73 | 2023-2025 | Repatha, Repatha |
| Abbott Laboratories | $250.69 | 2024-2025 | Proclaim, Eterna, Perclose Prostyle |
| Nalu Medical, INC. | $147.06 | 2025 | Nalu Neurostimulation System |
| Neurocrine Biosciences, INC. | $117.13 | 2025 | |
| Insulet Corporation | $113.51 | 2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.77 | 2025 | Caplyta |
| Alkermes, INC. | $59.54 | 2025 | Aristada, Lybalvi |
| Exact Sciences Corporation | $45.49 | 2025 | The Cologuard Plus Collection Kit |
| Kiniksa Pharmaceuticals International, Plc | $42.43 | 2024 | Arcalyst |
| Teva Pharmaceuticals USA, INC. | $41.03 | 2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $36.10 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $27.19 | 2025 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $25.86 | 2025 | Talicia |
| Csl Behring | $19.43 | 2025 | Privigen |
| Abiomed | $18.24 | 2024 | Impella |
| Novo Nordisk INC | $15.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.